Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome.
Duodenal-Jejunal Bypass Liner (DJBL) improves cardiovascular risk biomarkers and the predicted 4-year risk of major CV events in patients with Type 2 diabetes and metabolic syndrome.